These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 11961896)

  • 41. Chemical penetration enhancers: a patent review.
    Ahad A; Aqil M; Kohli K; Chaudhary H; Sultana Y; Mujeeb M; Talegaonkar S
    Expert Opin Ther Pat; 2009 Jul; 19(7):969-88. PubMed ID: 19552513
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Delivery of a classical antihypertensive agent through the skin by chemical enhancers and iontophoresis.
    Nair A; Reddy C; Jacob S
    Skin Res Technol; 2009 May; 15(2):187-94. PubMed ID: 19622129
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Microprocessor-controlled iontophoretic drug delivery of 5-fluorouracil: pharmacodynamic and pharmacokinetic study.
    Chandrashekar NS; Shobha Rani RH
    J BUON; 2007; 12(4):529-34. PubMed ID: 18067212
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Parenteral administration of progestins for hormonal replacement therapy.
    Nath A; Sitruk-Ware R
    Eur J Contracept Reprod Health Care; 2009 Apr; 14(2):88-96. PubMed ID: 19340703
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Transdermal antihypertensive drugs.
    Lancet; 1987 Jan; 1(8524):79-80. PubMed ID: 2879179
    [No Abstract]   [Full Text] [Related]  

  • 46. [Short term hormonal implantations].
    J Med Bord; 1952 Dec; 129(12):1172. PubMed ID: 13045059
    [No Abstract]   [Full Text] [Related]  

  • 47. [Alnagon].
    Melich H
    Cesk Farm; 1966 Jan; 15(1):61-2. PubMed ID: 5907964
    [No Abstract]   [Full Text] [Related]  

  • 48. Banning of hormonal implants.
    Milligan WA
    Vet Rec; 1986 Nov; 119(22):558. PubMed ID: 3798706
    [No Abstract]   [Full Text] [Related]  

  • 49. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Transdermal therapeutic systems].
    Makó S; Stampf G
    Acta Pharm Hung; 2001 Oct; 71(3):293-9. PubMed ID: 11961896
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
    Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
    Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Design and in vivo evaluation of an indapamide transdermal patch.
    Ren C; Fang L; Ling L; Wang Q; Liu S; Zhao L; He Z
    Int J Pharm; 2009 Mar; 370(1-2):129-35. PubMed ID: 19114099
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vitro release study of transdermal delivery systems of progesterone.
    Valenta C; Biebel R
    Drug Dev Ind Pharm; 1998 Feb; 24(2):187-91. PubMed ID: 15605451
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Transdermal therapeutic systems for drug administration].
    Hupfeld S; Gravem H
    Tidsskr Nor Laegeforen; 2009 Mar; 129(6):532-3. PubMed ID: 19282891
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Transdermal delivery of sex steroids for hormone replacement therapy and contraception. A review of principles and practice.
    Henzl MR; Loomba PK
    J Reprod Med; 2003 Jul; 48(7):525-40. PubMed ID: 12953327
    [TBL] [Abstract][Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.